Key result
Enoxaparin use in patients undergoing total hip arthroplasty resulted in transient hepatic enzyme elevations in up to 75% of patients, without clinical evidence of hepatic lesions.
Why the study?
Does enoxaparin cause hepatic changes in patients undergoing total hip arthroplasty?
Observational (n=32)
Does enoxaparin cause hepatic changes in patients undergoing total hip arthroplasty?
Answers are grounded in this paper and cite their sources.
Enoxaparin use for DVT prophylaxis in total hip arthroplasty frequently causes transient, asymptomatic elevations in hepatic enzymes that resolve after discontinuation.
OBJECTIVE: To evaluate hepatic changes resulting from the use of enoxaparin for prophylaxis of deep vein thrombosis among patients undergoing total hip arthroplasty. METHODS: Thirty-two patients underwent elective total hip arthroplasty, using enoxaparin, and were followed up for 65 days with serial hepatic enzyme assays. RESULTS: Changes in laboratory parameters were found in up to 75% of the patients during the study, but the parameters normalized after suspension of the treatment. No clinical evidence of hepatic lesions was found. CONCLUSION: The hepatic enzyme levels increase in most patients using enoxaparin, but without clinical correlation, and the levels normalize after suspension of the treatment.
No takes yet. Share an insight, caveat, or question.
Wink et al. (2010) conducted an observational in Total hip arthroplasty (n=32). Enoxaparin was evaluated on Changes in laboratory parameters (hepatic enzyme assays). Enoxaparin use in patients undergoing total hip arthroplasty resulted in transient hepatic enzyme elevations in up to 75% of patients, without clinical evidence of hepatic lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: